Floatz logo

Empagliflozin

Fibrosis, Liver

Military University Hospital, PragueSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

26 Active assets in the Fibrosis, Liver cohort.

Asset / SponsorPhaseRating
Entecavir
Tanta University
Phase 4BB
COLCHICINUM
Zagazig University
Phase 4BB
Peg-Intron
Beth Israel Deaconess Medical Center
Phase 4BB
Peg-Ifn
Beijing Friendship Hospital
Phase 4BB
A THERAPEUTIC PEGYLATED FIBROBLAST GROWTH FACTOR 21 AGONIST/MIMETIC WHICH RESTORES LEPTIN RESPONSIVENESS
Bristol-Myers Squibb
Phase 2BB

View all 50 →

Same molecule, other indications

Empagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Hypoglycemic AgentsDormant
BBB
Indicative ·
75 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →